Navigation Links
Experimental antibody shows early promise for treatment of childhood tumor

Tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital. Four patients are still alive after more than two-and-a-half years and without additional treatment.

Findings from the Phase I study were published recently online and will appear in the May 10 edition of the Journal of Clinical Oncology. The results prompted St. Jude to expand clinical trials of the monoclonal antibody hu14.18K322A to include patients newly diagnosed with neuroblastoma. Monoclonal antibodies are engineered in the laboratory to recognize and attach to specific markers carried on the cell surface.

Neuroblastoma is a cancer of the sympathetic nervous system. It is the most common cancer diagnosed in the first year of life and accounts for 7 to 10 percent of childhood cancers. While certain patients, particularly infants, enjoy cure rates of 90 percent or better, the outlook is worse for high-risk patients, including those whose disease has spread widely. New treatments are urgently needed for these patients, less than half of whom currently enjoy long-term, disease-free survival.

"This was the first time this experimental antibody was tried in patients. We were encouraged with the response," said first and corresponding author Fariba Navid, M.D., an associate member of the St. Jude Department of Oncology. "The percentage of patients who benefited from treatment with hu14.18K322A was unusual for a Phase I study."

Phase I studies focus on questions related to the safety and best dose of experimental therapies. The research involves patient volunteers whose cancer has returned or did not respond to standard treatment, which for neuroblastoma includes surgery, chemotherapy, radiation and bone marrow transplants.

In this study, 38 St. Jude patients received one of nine different doses of hu14.18K322A. The immunotherapy is designed to activate the disease-fighting immune system to attack and kill tumor cells. Every 28 days, patients received an infusion of hu14.18K322A once daily for four days.

Of the 31 patients evaluated after two or more rounds of treatment, the disease stabilized in nine patients, tumors shrank in two patients and were undetectable in four more, researchers reported. "Four patients are alive after more than two-and-a-half years without additional therapy," Navid said.

Hu14.18K322A is an antibody engineered to recognize and attach to a molecule called the GD2 antigen. GD2 is found on the surface of almost all neuroblastoma cells as well as other tumors, including the skin cancer melanoma, the bone cancer osteosarcoma and soft-tissue sarcomas. The antigen is found on the normal cells of just a few tissues.

The antibody is produced in the Children's GMP, LLC. Navid said the study would not have been possible without the GMP, an on-site facility that makes highly specialized medicines and other biologics under government-approved Good Manufacturing Practices regulations.

The monoclonal antibody in this study is one of several antibodies targeting GD2 that are in clinical development for treatment of neuroblastoma. Hu14.18K322A is a modified version of another antibody. The main change, a point mutation in the human gene for hu14.18, was designed to address treatment-limiting pain by generating a more tailored response that avoided triggering part of the immune response called the complement cascade. In addition, the hu14.18K322A has fewer mouse components, making it less likely the body will reject the antibody. It is also made in a cell line that may improve its ability to kill tumor cells.

In this study, pain remained the most common side effect associated with hu14.18K322A treatment. While 68 percent of patients reported severe pain during the first round of treatment, Navid said the pain was manageable with medication and resolved within 24 hours of receiving the experimental antibody. The pain also lessened with each round of therapy. While direct comparisons between patients who received hu14.18K322A and a different version of the antibody are difficult, Navid said: "Our clinical impression is that the duration and severity of pain in patients receiving hu14.18K322A are less."

Clinical trials involving hu14.18K322A continue at St. Jude. Researchers are testing the impact of giving the monoclonal antibody weekly rather than every 28 days and in combination with other therapies.


Contact: Summer Freeman
St. Jude Children's Research Hospital

Related medicine news :

1. Experimental drug prolongs life span in mice
2. Experimental drug shows promise for treatment-resistant leukemias
3. Diabetes drug shows promise in reducing Alzheimers disease in an experimental model
4. Experimental drug could enhance multiple myeloma and myeloid leukemia therapies
5. Experimental drug shows encouraging results in treating most common form of lung cancer
6. Studies of experimental hepatitis C drug show promise for preventing recurrence in liver transplant
7. ASSURE study of experimental agent to raise HDL yields disappointing and surprising results
8. York physicists offer novel insight into experimental cancer treatment
9. Experimental Drug Shows Benefits Against Melanoma in Early Study
10. Experimental Drugs Show Promise Against Prostate Cancer
11. Experimental Drug Seems to Aid Memory in Mice With Alzheimers
Post Your Comments:
(Date:11/30/2015)... ... November 30, 2015 , ... According to an article published ... but slightly unusual choice to show her Instagram followers that the praise that they ... been pre-mature. Saying that she didn’t “want to mislead any mommy's who just had ...
(Date:11/30/2015)... Los Angeles, CA (PRWEB) , ... November 30, 2015 , ... ... hunger cravings that drive people to overeat are not necessarily caused by real hunger, ... brain that the stomach needs food. He notes that, while many patients are aware ...
(Date:11/30/2015)... ... November 30, 2015 , ... Cycling, running, and walking ... on extra meaning the morning of February 28, 2016. , That’s when the ... and thousands will exercise to help children and families at Joe DiMaggio Children’s ...
(Date:11/30/2015)... ... November 30, 2015 , ... RoamRight, a leading provider of travel ... Public Television’s Travel With Kids to promote family vacations around the world. The ... explore international destinations and educate families about the people and places of the world, ...
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of ... be effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant ... that small molecule analogs that target the functions of SecA, a central part ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... 2015   Royal Philips (NYSE: PHG ... first MRI guided user interface and automatic scan parameter ... MR Conditional implants, such as knee and hip replacements, ... Society of North America Annual Meeting (RSNA) . The ... confidence of this growing patient population. ScanWise Implant adds ...
(Date:11/30/2015)... -- North America was valued at ... a CAGR of 7.6% from 2015 to 2020. --> ... in 2014, and is expected to grow at a CAGR of ... new Market Research Report "North America Cardiac Output Monitoring Devices Market ... care, others) - Analysis And Forecast To 2020", the cardiac output ...
(Date:11/30/2015)... KONG, Nov. 30, 2015 (HK$,000)For the Six Months Ended 30 September 2015 ... Income , 421,979 , 384,242 , ... , 34,719 , (18.3) Medical Insurance ... , 16.1 Medical Devices and Accessories Sales , ... Chinese Herbal Medicines Sales , 2,822 , ...
Breaking Medicine Technology: